论文部分内容阅读
肺癌在全世界范围内的发病率和病死率居恶性肿瘤之首,其发病率逐年升高,严重影响着人类的生命健康,其中非小细胞肺癌(NSCLC)占80%左右,约3/4的NSCLC患者在初诊时即已发生转移。NSCLC患者在进行根治性切除后,5年生存率也只有25%~30%,患者多死于复发转移。以铂类药物为基础的联合
The incidence and mortality of lung cancer in the world ranks first in malignant tumors, the incidence increased year by year, seriously affecting human life and health, of which non-small cell lung cancer (NSCLC) accounted for about 80%, about 3/4 Of NSCLC patients have already metastasized at the time of their first visit. After radical resection in NSCLC patients, the 5-year survival rate is only 25% to 30%, and more patients die of recurrence and metastasis. Platinum-based drug combination